


This is where Polish innovation begins





Our mission



We respond
to the key challenges
of modern medicine

**ADAMED**
For the Family

Dear Sir or Madam,

The history of Adamed is about responding to the key challenges of modern medicine. This is both our mission and the direction we have consistently taken since 1986. Every day, we work with numerous scientists on innovative research projects aimed at improving existing therapies and promoting disease prevention and a healthy lifestyle. To achieve our goals, we employ the best specialists in the country and collaborate with leading scientific centres and institutions, while employing state-of-the-art technologies in all areas of our operations.

All this makes Adamed a leader in the next-generation pharmaceutical market in Poland. Our products are available in dozens of markets all over the world. Even with this success, we have no intention of resting on our laurels. We continue to evolve and to search for inspiration and unconventional solutions.

We encourage you to learn more about Adamed Pharma – the place where Polish innovation begins.

Yours faithfully

Małgorzata Adamkiewicz, MD, PhD
President of the Supervisory Board of Adamed Pharma



History of Adamed Pharma

Adamed established by Marian Adamkiewicz, MD, PhD



1986

First manufacturing plant opened in Pieńków near Warsaw




1994


R&D division established



1999



Furaginum market introduction - used for lower urinary tract infections




Registration of the first Polish amlodipine - the first product manufactured using our patented manufacturing process



GMP certification confirming our adaptation to EU manufacturing standards obtained

Research on innovative medicines initiated

Lutein market introduction - a drug used for menstrual cycle disorders and infertility



2001

2002



Second manufacturing plant opened in Ksawerów, near Łódź



European exports begin

Amplodipin registration in the European Union, before Poland's accession to the EU

2003

2005 - 2009



First science and industry consortium established



Representative office in Ukraine established



Adamed Laboratorios starts operating in Spain



Acquisition of Polfa Pabianice and Agropharm

2010

2011 - 2012




Representative office in Russia established

 Representative offices in the Czech Republic and Slovakia established

Research and Development Centre inaugurated

Pilot Plant in Pabianice established

 Representative office in Kazakhstan established



2013

2013 - 2015



2016

2017



2018



State-of-the-art Research and Development Centre built

Development of AD-051.4 - an innovative anticancer molecule developed as a part of the ONCO-3CLA project - begins



 Acquisition of a controlling stake in a Vietnamese company Davipharm

 Representative office in Italy established

Acquisition of shares in Ecupharma



2019

2020



An exclusive global license agreement is signed with Acadia Pharmaceuticals for further development of Adamed's innovative molecule

 Establishment of a representative office in Uzbekistan

Expansion of the Production and Logistics Center in Pabianice



2021

2022



Acquisition of a laboratory in Kajetany

First in the world Rx-to-OTC switch of Tadalafil 10 mg

 Acquisition of 100 percent shares of the Vietnamese company Davipharm



2023



About us



Company profile

Adamed Pharma is a Polish pharmaceutical and biotechnology company manufacturing almost 900 products (so-called SKU) offered to patients in several dozen countries worldwide. It currently has more than 2,700 employees. The company has been working with leading universities and research institutes. In 2023, Adamed was listed on the 3rd place in the ranking of pharmaceutical companies operating in Poland, taking into account value sales to the patient. (source: PEX)



3
production plants

2 in Poland and 1 in Vietnam
over 3 billion tablets a year



almost 900
products (so-called SKU)
in Adamed's portfolio
in Poland and around the world



over 2,700

Adamed employees in Poland
and around the world



3 research platforms

- oncology
- neuropsychiatry
- diabetology



19 therapeutic areas


- Allergology
- Angiology
- Vascular surgery
- Dermatology
- Diabetology
- Gastroenterology
- Gynaecology
- Internal medicine
 - Cardiology
 - Laryngology
 - Neurology
 - Oncology
- Ophthalmology
- Orthopaedics
- Paediatrics
- Pulmonology
- Psychiatry
- Rheumatology
- Urology

1st place among employers in the pharmaceutical and biotechnology industry
15th place for Adamed Pharma in the general overview in 2024 in the prestigious
Forbes Polska Rank: Poland's Best Employers 2024
7th place in 50 Best Polish Employers Rank by Wprost weekly

Adamed Group revenue*

2017-2024

Net sales, EUR mln



Source: internal data (Ex-factory) | Data corrected for the difference in list and actual prices for oncology products, so-called onco-rebates

*The Adamed Group consists of Adamed Pharma, Davipharm (shares since 2017) and Ecupharma (shares since 2019).

This is where Polish innovation begins

Adamed was created basing on its own scientific ideas and its own patents. Since 2001, we have invested almost 500 million EUR in R&D activity and capital investments. In 2016, we opened a modern, 3,000 square metre R&D Centre, fully furnished with state-of-the-art research infrastructure.

In 2022, as part of its activities under the New Drug Discovery strategy, Adamed Pharma has purchased facilities with laboratory infrastructure based in Kajetany near Warsaw. Over the next few years, the site will allow the implementation of new drug development projects.



~500 M EUR

in R&D activity
and capital investments
since 2001



2016

inauguration of our
state-of-the-art Research
and Development Centre



3,000 m²

of laboratory space



2018

inauguration of
Pilot Plant



2022

acquisition of facilities
with laboratory
infrastructure based
in Kajetany near Warsaw



250 innovative and generics
patents



90 inventions

Adamed's R&D Center has been established with the purpose of implementing research projects. These projects aim to improve the existing therapies and search for new drugs relying on organic synthesis and new technologies, and to provide support through physical and chemical analysis. The Center runs projects in the lab phase and the semi-industrial phase to enable the transfer of technologies to Adamed Pharma's manufacturing facilities. The two-storey laboratory building is equipped with a modern facility management system and number of other systems for the effective and safe operation of laboratories, including purified water and technical gas distribution systems, local

contaminated air exhaust systems, and systems for maintaining and monitoring stable climate and fire-fighting conditions.

The formulation and technology laboratory has been built as a class-D pharmaceutical facility with a higher air purity standard to accommodate the technologies being developed there.

Our experts at the research and development (R&D) labs use the latest technological advancements and modern equipment to develop both basic and more original dosage forms such as multilayer tablets, over-encapsulated tablets etc. The state-of-the-art analytical equipment available in the laboratories, such as SEM, XRPD, UPLC/MS, and expertise backed by experience place us at the forefront of the pharmaceutical companies relying on innovation in their R&D activities.

Research and Development Activities

Research and development activities in Adamed Pharma are conducted in two areas: innovative and generic. The work on interdisciplinary development projects in these areas is also supported by other teams responsible for registration, clinical research, project management and intellectual property protection.

The generic area brings together high-level experts who introduce elements of innovation into the work on generic drugs to accommodate patients' needs. Well-equipped laboratories for organic synthesis, formulation and technology, and analytics make it possible to effectively implement even very ambitious and multi-stage research projects.

Innovation Area responsible for early development of original drugs (discovery, pre-clinical stage) comprises a number of closely cooperating units: Data Modelling & Analysis Lab, Biotechnology and Recombinant Proteins Team, In Vitro Pharmacology Team, In Vivo Study Team and Pre-clinical Development Lab. Numerous scientists from Polish and foreign academic institutions and biotechnology companies provide a significant support to the personnel at the units specified above. The organic synthesis, analytic and investment funding departments provide inhouse support within our organization.



Research platforms

Oncology platform

ONC051 (AD-051.4)

The purpose of the project is to develop a biotechnology drug candidate, a fusion protein based on the TRAIL molecule. AD-051.4 is characterised by a dual pro-apoptotic and antiangiogenic mechanism of action, owing to which the candidate molecule has demonstrated to be highly effective in various oncological indications in in-vivo and in-vitro preclinical studies. Preclinical evaluation of the molecule was completed in the project. The on-going production of the molecule in the clinical trial batch will make it possible to start phase I of clinical trials. The aim of the project is to pass the molecule through phases Ia and Ib.

Project co-financed from the State budget by the Medical Research Agency, in the Competition for the Development of Targeted or Personalised Medicine Based on Cell Therapies or Protein Products.



Fundusze Europejskie



AGENCJA
BADAŃ
MEDYCZNYCH

ONCO-32 (AD-021.32)

AD-021.32 is a small-molecule anticancer compound whose mechanism of action is inhibition of Mdm2-p53 binding, reactivation of the p53 protein and induction of apoptosis of cancer cells. The clinical candidate AD-021.32 is more effective than its available competitors, as demonstrated in in-vitro studies and in in-vivo mouse xenograft studies. It is characterised by high bioavailability and its oral dosing causes a complete remission of sensitive tumour models. The molecule also exhibits synergistic effects in numerous drug combinations. The project is now at the stage of completed preclinical trials necessary for the initiation of phase 1 first-in-human (FiH) studies in cancer patients. Preparations for the initiation of the clinical trial are on-going.

The value of the project is PLN 34,749,466.78, of which PLN 18,170,000 are the funds of the National Centre for Research and Development granted under the Fast Track Programme for Mazovia for the project "Clinical development of an innovative anticancer compound relying on p53 protein activation" "MAZOWSZE/0012/19-00". The value of the project is almost PLN 35 million, of which over PLN 18 million are funds from the National Centre for Research and Development.



Fundusze Europejskie

NCBR
Narodowe Centrum Badań i Rozwoju

AD-064 series

The INFTRAIL project is implemented as part of a panel of proof-of-concept projects for new therapy candidates. Its purpose is to investigate the therapeutic potential and safety of biotechnological molecules which are a combination of two cytokines with pro-apoptotic and immunostimulating activities in cancer treatment. The project involves the conduct of research on the selection of safe doses as well as on the potential for immune system activation and on anti-cancer activity in syngenic animal models. In addition, processes for obtaining selected molecules for future production for the purposes of toxicological and clinical studies are being optimised.



Neuropsychiatry platform

Research conducted as part of the neuropsychiatry platform is aimed at developing innovative drug candidates for the treatment of central nervous system disorders which currently pose the greatest civilization challenges, such as mood disorders, schizophrenia and Alzheimer's disease. The research is being carried out in close cooperation with leading research centers in Poland, such as the Medical College at the Jagiellonian University and the Institute of Psychiatry and Neurology in Warsaw. The key achievement of the research work carried out under the neuropsychiatry platform is the development of a drug candidate (as part of an advanced preclinical development phase) which was commercialized for a US company Acadia Pharmaceuticals in late 2020. Acadia is a pioneer in the development of antipsychotic drugs with a non-dopaminergic mechanism of action, and is responsible for further pharmaceutical development of the drug candidate as part of the collaboration. The current research activities of the neuropsychiatry platform focus on searching for innovative drug candidates for the treatment of drug-resistant depression.



SORAAD

The purpose of the project is to meet the currently most important medical needs in the pharmacotherapy of depression, such as the rapid onset of drug action, reduction of side effects and oral bioavailability. This is to be achieved through specific modulation of a combination of receptors and transporters in the central nervous system by a small molecule with advantageous physicochemical properties. The project is carried out in cooperation with our long-term academic partners from the Collegium Medicum of the Jagiellonian University.



UNIWERSYTET JAGIELLOŃSKI
COLLEGIUM MEDICUM

Diabetology platform

DILOC2

The purpose of DILOC2 is to develop a medicine that would combine the convenient oral route of administration and an innovative approach to the mechanism of action, so as to fully exploit the incretin effect in the treatment of patients with obesity. Obesity is the key non-genetic risk factor for serious cardiometabolic conditions, disability or premature death. The final result of the project will be the patent-protected structure and technology of manufacture of a molecule with the characteristics that will potentially enable it to obtain the “best in class” status.

Until 2023, the project was subsidised by the National Centre for Research and Development.



Infectious diseases

Vaccine1

The Vaccine1 project is being implemented by a consortium involving Adamed Pharma, the University of Gdańsk and the Institute of Biochemistry and Biophysics of the Polish Academy of Sciences. The main objective of the project is to develop a recombinant mRNA/VLP-based vaccine against zoonotic pathogens that pose a threat to human health. The new mRNA/VLP-based vaccine is expected to be characterised by greater safety and to provide better protection against infection than the existing vaccines. Moreover, it should be possible to store it at 4°C without loss of quality. Adamed Pharma is the leader of the consortium and the partner responsible for delivering the technology for the manufacture of the drug candidate which will be provided by the scientific entities, and for conducting clinical trials of this medicine. The total value of the project is over PLN 87 million, of which almost PLN 60 million is financed from the State budget by the Medical Research Agency.



AGENCJA
BADAŃ
MEDYCZNYCH




INSTITUTE
OF BIOCHEMISTRY
AND BIOPHYSICS
POLISH ACADEMY
OF SCIENCES



Uniwersytet
Gdański




Pipeline



Our science partners:

- Institute of Biochemistry and Biophysics, Polish Academy of Sciences in Warsaw,
- Institute of Physical Chemistry, Polish Academy of Sciences in Warsaw,
- Pharmaceutical Research Institute,
- Institute of Pharmacology, Polish Academy of Sciences in Krakow,
- Institute of Industrial Organic Chemistry, Branch Office in Pszczyna,
- University of Gdańsk,
- University of Warsaw,
- Medical College, Jagiellonian University,
- The John Paul II Catholic University in Lublin,
- Medical University of Gdańsk,
- Medical University of Warsaw,
- Wrocław University of Science and Technology,
- International Institute of Molecular and Cell Biology,
- International Center for Cancer Vaccine Science,
- Professor Zygmunt Wasylewski Foundation for the Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University,
- Łukasiewicz Research Network – PORT Polish Center for Technology Development.



Adamed's modern Production and Logistic Centre

In an age of globalisation and fierce competition, the quality of the products on offer is of the utmost importance, while maintaining optimum production costs and a high level of customer service. The modern Production and Logistics Centre is located in the Łódzkie Voivodeship.

It is also the showcase of the Łódz region and a reliable employer of a highly-qualified workforce. It is important to implement good practices from other sectors, where the management of the broadly under-

stood supply chain is an important source of competitive advantage. Early 2022 saw the completion of another stage of expansion of the Production and Logistics Centre. Through this investment, we are set to improve access to medicines for patients in Poland. By expanding the Pabianice plant, we will enhance its production capacity from 2 billion tablets (2020) to 4 billion tablets (2027) and will increase the level of automation and robotisation of processes.





Production and Logistic Centre in Poland

2 PRODUCTION SITES



2.6 billion tablets a year



quality & compliance



Production pillars:

cGMP

RiskManagement

KAIZEN

TPM/SMED/Simple Processes



71 million packages a year

7,000 batches released per year



Every year, the Centre is subject to a dozen inspections and audits carried out by contractors – mostly large multinational companies.

The Centre is equipped with several dozen manufacturing and tablet packaging machines

Our competitive edge:

→ reliability

→ flexibility

Your contract manufacturing partner

- multi-dose capsules
- tablets

Our expertise includes technology transfer and contract manufacturing of medicines in solid forms, such as tablets and hard capsules (medicinal products and supplements), and is backed up by an extensive list of references worldwide.

We are pleased to offer our customers versatile services tailored to their individual needs through access to our world-class facilities and high-level scientific input into each project.

We manufacture the following forms of products and intermediates:

- Hard multi-dose capsules (pellets, powder, granulations, tablets, micro-doses for inhalation products, micro-tablets, liquid forms),
- Immediate release tablets,
- Controlled-release tablets,
- Fast disintegrating tablets,
- Film-coated tablets,
- Multi-layer tablets,
- Products manufactured using the direct tableting/encapsulation process,
- Wet granulations (obtained using fluid methods and high shear granulator mixers),
- Dry granulations obtained by compacting (including with selective particle size distribution).

We apply cGMP production standards:

- Sourcing and qualification of manufacturers of active agents, excipients, and packaging materials,
- Preparing quality documentation and releasing raw materials for production,
- Mixing,
- Granulation,
- Compression/encapsulation,
- Coating,
- Blistering,
- Unit packaging,
- Stability testing,
- Releasing for sale,
- Preparation of e-CTD documentation for registration purposes,
- Storing archive samples.

Multi-dose capsules

Currently available dosing systems:

micro-dosing

up to 72,000 capsules per hour
100% control of capsule content



pellets

up to 100,000 capsules per hour, two chambers which are alternately filled and emptied



tablets

60,000-100,000 capsules per hour, depending on the number of tablets to be dosed per capsule and on the size and shape



Other potential combinations of capsule products:

- Powder,
- Liquid,
- Up to three pellet types with different active ingredients,
- Up to three tablet types with different active ingredients,
- Micro-tablets,
- Capsules,
- Combination: pellets, capsule, and tablet,
- Combination: powder, tablet, and pellets,
- Combination: tablet and two pellet types with different active ingredients,
- Combination: powder and two tablet types with different active ingredients,
- Combination: powder and liquid.

Capsule size: 00, 0, 1, 2, 3, 4.

Capsule types: hard gelatine capsules, HPMC.

You can order both small and large batches manufactured in compliance with the highest quality standards and with short turnaround times.

Pilot Plant

Within the Research and Development Division, 2017 saw the completion of the Pilot Plant, an investment in R&D pilot production. This project received funding from European Union structural funds.

Pilot production of previously developed prototypes is an essential stage of the R&D process and a necessary precondition for the successful completion of development work and, in the long-term, for obtaining a marketing authorisation permit and for production scale-up. Extending our organisational structure to include the specialist pilot drug candidate manufacturing area will translate into a range of benefits, including:

- fast and flexible implementation of R&D projects by making them independent of current production schedule,
- efficient identification, optimisation, and validation of critical manufacturing parameters defined at the laboratory R&D stage,
- development of guidelines for manufacturing and quality control processes,
- supply of products for conducting clinical studies.

The new technologies which have been acquired for the Pilot Plant, including a multilayer tablet press, a Hot Melt Extrusion (HME) machine, and a fluid granulator, will also create more opportunities for R&D activities related to next-generation products. Introducing pilot production lines involving multilayer tableting or extrusion techniques (innovative on a national scale) will enable the development of semi-products and final forms of medicinal products with the added value necessary for securing a competitive advantage, which is difficult to accomplish with standard pharmaceutical processes.

The Pilot Plant was formally inaugurated in April 2018.



Fundusze Europejskie
Inteligentny Rozwój

Unia Europejska
Europejski Fundusz
Rozwoju Regionalnego





Business development



International expansion

Adamed started its international expansion in 2003. As of today, its products are available in a dozens of countries worldwide, including in Europe, the Middle East, Asia, Africa, Latin America, and Oceania. Adamed Pharma has 8 representative offices. A consistently implemented development strategy based on innovation and international expansion has made the company a renowned global brand. For many years, Adamed Pharma has recorded a steady increase in the volume and value of its product sales. International operations currently account for a third of the overall business, and the development plans anticipate a further increase in this share to 55%.



● Head Office: Pieńków near Warsaw, Poland

Representative offices: 

Investment in Asia



Adamed Pharma is a 100% shareholder of Davipharm. Adamed Pharma has thus become the sole owner of the Vietnamese company, one of the fastest growing pharmaceutical companies in this part of Asia. To date, Adamed's capital involvement in Vietnam has amounted to nearly USD 60 million. This is one of the largest Polish direct investments in this part of the world.

Currently, foreign markets account for nearly 40 percent of Adamed Pharma's revenue. In the medium term, the objective is to achieve a 50:50 ratio, while in the ten-year horizon it is foreign revenue that is expected to predominate in the company's overall revenue. Owing to the Vietnamese investment, Adamed Pharma will further expand its operations in Asia and export its drug products to highly regulated markets. The acquisition of a 100 percent stake in Davipharm not only underscores the importance of the Vietnamese market in the company's development plans, but is also a testament to Adamed's strategy, a key element of which is international expansion.





License-out

The License-out team is a group of experienced professionals responsible for the sale of Adamed products worldwide. We are open to different business models, including licensing, distribution, co-development of new products, and contract manufacturing. We are also responsible for the sale of licenses to third parties. We provide full support within the scope of regulatory affairs and intellectual property, new product launch strategies, and open cooperation. All this is to ensure the successful implementation of new products with minimum risk and at competitive prices. We provide our business partners with registration dossiers for ready-made drugs, prepared in the CTD format, which meet the strictest requirements set out in the GMP and stipulated by regulatory agencies around the world. Thanks to the License-out team's experience, we can offer the highest quality of partnership based on a win-win strategy.

Representative offices in Eastern Markets

Since 2005, Adamed has been very active in the Commonwealth of Independent States through its representative offices in Kiev, Moscow, and Almaty. Our long-standing presence in Eastern Europe has made us familiar with the needs of patients in this region. To meet their expectations, we are continually enriching our portfolio with new Rx and OTC products in nearly all therapeutic areas.

We make use of novel promotion and sales management tools such as a CRM system, databases, market monitoring, and geo-marketing. Adamed's most important achievements in the eastern region include over 100 products on the market, a dozen new launches per year, and a strategy for maintaining high growth dynamics.

In 2014, Adamed was rated among the fifty best pharmaceutical employers in Ukraine. It was also ranked the country's 10th fastest-growing company.

License-in

The License-in Department is engaged in obtaining new product offers, which are then gradually added to Adamed's portfolio. The department is responsible for short-listing the available offers, conducting successful negotiations, and signing agreements with selected contractors. The company is in close contact with all the largest generics companies in Europe and beyond. This allows us to continuously survey the pharmaceutical market to spot the available molecules and expiring patents and to identify new business opportunities.

License-out offer

We are always vigilant and respond to changes in both domestic and foreign markets. We are constantly searching for new markets where our products could make their mark.

CARDIOLOGY

- CANDESARTAN + AMLODIPINE 8mg/5mg; 8mg/10mg; 16mg/5mg; 16mg/10mg, capsules
- CANDESARTAN + AMLODIPINE + HCTZ **NEW**
16mg/5mg/12,5mg; 16mg/10mg/12,5mg, capsules
- CILOSTAZOL 50mg; 100mg, tablets
- DABIGATRAN 75mg; 110mg; 150mg, capsules **NEW**
- EPLERENONE 25mg; 50mg, coated tablets
- EZETIMIBE + ROSUVASTATIN
10mg/5mg; 10mg/10mg; 10mg/15mg; 10mg/20mg;
10mg/30mg; 10mg/40mg, tablets **NEW**
- PERINDOPRIL TERT-BUTYLAMINE + AMLODIPINE
4mg/5mg; 4mg/10mg; 8mg/5mg; 8mg/10mg, tablets
- RAMIPRIL + AMLODIPINE 2,5mg/5mg; 5mg/5mg;
5mg/10mg; 10mg/5mg; 10mg/10mg, capsules
- RAMIPRIL + AMLODIPINE + HCTZ
5mg/5mg/25mg; 10mg/5mg/25mg; 5mg/5mg/12,5mg;
10mg/10mg/25mg, capsules
- RAMIPRIL + BISOPROLOL 2,5mg/1,25mg;
2,5mg/2,5mg; 5mg/2,5mg; 5mg/5mg; 10mg/5mg;
10mg/10mg, capsules
- RAMIPRIL + INDAPAMIDE SR 5mg/1,5mg; 10mg/1,5mg;
modified release tablets **NEW**

- RANOLAZINE 375mg; 500mg; 750mg,
extended release tablets **NEW**
- RIVAROXABAN 2,5mg; 10mg; 15mg; 20mg,
coated tablets **NEW**
- ROSUVASTATIN 5mg,10mg,15mg,20mg,30mg,40mg
coated tablets
- ROSUVASTATIN + ACETYSALICYLIC ACID
5mg/100mg; 10mg/100mg; 20mg/100mg, capsules
- ROSUVASTATIN + AMLODIPINE 10mg/5mg;
10mg/10mg; 20mg/5mg; 20mg/10mg, capsules
- TELMISARTAN + ROSUVASTATIN
40mg/10mg; 40mg/20mg; 80mg/10mg; 80mg/20mg,
coated tablets **NEW**

CENTRAL NERVOUS SYSTEM

- B1 + B6 + B12 Vitamin Complex 150mg/50mg/0,2mg,
coated tablets **NEW**
- DULOXETINE 30mg; 60mg,
enteric-coated tablets
- OLANZAPINE 5mg; 10mg, tablets
- OLANZAPINE ODT 5mg; 10mg; 15mg; 20mg,
orodispersible tablets
- PREGABALIN 25mg; 50mg; 75mg; 100mg; 150mg;
200mg; 225mg, 300mg; capsules

DIABETOLOGY

- LINAGLIPTIN, 5mg, coated tablets **NEW**
- SITAGLIPTIN 25mg; 50mg; 100mg, coated tablets
- SITAGLIPTIN + METFORMIN XR
50mg/500mg; 50mg/1000mg; 100mg/1000mg;
modified release tablets

GYNAECOLOGY & UROLOGY

- SILDENAFIL 25mg, 50mg, 100mg, coated tablets
- SOLIFENACIN + TAMSULOSIN OCAS® 6mg/0,4mg,
extended release tablets
- TRANEXAMIC ACID 500mg, 1000mg, tablets **NEW**

ONCOLOGY

- ABIRATERONE 250mg; 500mg, coated tablets
- BORTEZOMIB 3,5mg, vial
- IMATINIB 100mg; 400mg, capsules
- SUNITINIB 12,5mg; 25mg; 37,5mg; 50mg, capsules

OTHER THERAPEUTIC AREAS

- AZITHROMYCIN 250mg; 500mg, coated tablets
- DEXAMETHASONE 4mg; 8mg; 20mg, tablets
- FLUDROCORTISONE 0,1mg, tablets
- RISEDRONATE SODIUM 35mg; 75mg,
coated tablets


OVER-THE-COUNTER DRUGS (OTC)

- CYTISINE 1,5mg, coated tablets
- CYTISINE 1,5mg, oral solution (spray) **NEW**
- FURAZIDIN 50mg; 100mg, tablets
- MINOXIDIL 5%, foam **NEW**
- SILDENAFIL 25mg; 50mg,
coated tablets (also available as RX) **NEW**

Adamed's revenues

export*

Net sales, EUR mln



* Internal data

Startups

Adamed has actively supported start-ups in Poland since 2015. To that end, the company has established a venture capital arm through which – beyond simply pursuing investment opportunities – it has been involved in several initiatives providing assistance to start-ups taking their very first steps in product development and developing their commercial operations.

Adamed has been involved in a series of acceleration programmes for budding technological companies, acting as a partner to support projects related to the healthcare sector. In recent years, these have included:

→ **MIT Enterprise Forum Poland and MIT Enterprise Forum CEE** – the programs are based on the know-how of the world's most renowned technical university, the Massachusetts Institute of Technology. As a partner to the Health path, Adamed provides the program participants with, among other things, support from experienced mentors, access to inhouse laboratory facilities, possibility to deploy pilot programs and help in building business models. Selected editions of the program were co-financed under the ScaleUp program of the Polish Agency for Enterprise Development (PARP), which made it possible to support startups with up to PLN 200,000. Adamed has been a partner to each of the editions of both programs carried out to date.

→ **Scale-up Champions**, an international initiative offering support for deep tech digital startups from all over Europe. It helps startups to venture into international markets, start collaborations with corporations and investors, and as a result, scale up their business.

→ **MedBiz Innovations** – mentoring program created for students of various faculties, including medical studies, to jointly create innovative solutions. Teams of students work on ideas for a product or service that combine modern technology, medicine and business. Projects with the highest potential for commercial application are further developed under supervision of experienced representatives of the MedTech sector.

→ **Science Startup** – an accelerator program implemented by the Subcarpathian Innovation Center aimed at shaping proinnovative and entrepreneurial attitudes and supporting Subcarpathian scientists in setting up academic startups. Science Startup offers mentoring, training sessions and networking activities to scientific teams.

→ **SmartUp Lab 2022** – educational and incubation program organized by the Medical University of Łódź. The program targets young innovators interested in developing creative solutions: students, PhD students, graduates, scientists and entrepreneurs who form interdisciplinary teams developing ideas and products under subject-specific mentoring.



Enterprise Forum
CEE

MedBiz
Innovations Program

2022
Smart-Up Lab



SCALE-UP
CHAMPIONS


ADAMED
For the Family



ESG



E

Reducing the negative impact on the environment

0%

of industrial waste ends up in landfills

96%

of the waste is sent for recycling or recovery

100%

of the industrial waste water at the Pabianice plant is ozonised

15%

of the energy demand of production plants are covered by photovoltaic installations



Compounded drugs



GHG counted
in scopes 1&2



Ozonisation of
industrial waste water



Compounded drugs

Adamed Pharma's experience shows that, through innovative solutions, we can combine the effective fulfilment of a patient's needs with a simultaneous reduction of the negative impact on the environment. It is often the case that patients have to take several or even more than a dozen tablets from different therapeutic areas. Thanks to the innovative technologies we develop and use, we can combine 2 or 3 substances into a single tablet or capsule. On the one hand, this makes it easier for patients to adhere to therapeutic recommendations - fewer tablets means less risk of confusion or missed doses. On the other hand, one drug also means one blister or cardboard box - meaning fewer resources needed for production and definitely less waste. This practice shows that our actions care for both the environment and society.



Ozonisation of industrial waste water

Adamed Pharma has introduced ozonation into the industrial wastewater treatment process at its manufacturing plant in Pabianice. Ozonation, used instead of chemicals, is an environmentally friendly solution that eliminates pharmaceutical micropollutants from discharged wastewater. The process is based on the use of ozone, which is a natural compound that is produced on site, without the formation of by-products or waste. Ozone, which is a renewable substance, breaks down the structures of chemical compounds in industrial wastewater through its properties, leading to effective treatment and reduction of pharmaceutical micropollutants. Ozonisation of wastewater, as a solution based on circular economy principles, enables the natural treatment of production wastewater without generating waste, and ensures safety for the aquatic ecosystem.



GHG counted in scopes 1&2

In order to effectively reduce CO₂ emissions, at first it is necessary to accurately determine the level of emissions. Therefore, in order to get a complete image of our emissions, we have calculated Adamed Pharma's Scope 1 and 2 carbon footprint (direct and indirect emissions) for 2022. We are continuing this process in order to make informed decisions in the future and to introduce substantive measures to reduce our negative impact on the environment

E

Implementation of initiatives in the field of decarbonisation and circular economy



ECO fleet

We are building a fleet of exclusively low-emission hybrid cars since 2019. The new hybrid cars use less fuel, thus we save at least one litre for every 100 km.



Blister recycling

Clean blisters consisting of aluminium foil and plastic are sent directly to a recycler which, after mechanical and electrostatic separation of the raw materials, sends the aluminium for smelting to a steel mill and uses the plastic (in powder form) to produce garden hoses and pickets for furniture and fences.



Reduction in energy consumption

We use energy-efficient LED lighting. Moreover in restrooms and corridors, we implement solutions to reduce electricity consumption by installing, among other things, motion sensors and occupancy sensors.



We educate and shape attitudes through practical actions: we organize eco-contests, plant and clean up forests, sow wildflower meadows, collect chestnuts and acorns for animals, and build houses for birds and insects.

S Adamed Pharma's Social Programs - For the Common Good


Ethics

Adamed's success comes not only from our performance and business agility, but most of all from our reputation as an ethical and trustworthy company. With us, operating within the law is a given. Still, we know that it takes more than that to build the company of our dreams. In addition

to legal regulations, at Adamed we respect good practices, industry standards, and the universal values, social norms, and ethical principles that foster a reliable and trustworthy business environment. We expect the same from our contractors and business partners.

Community programmes

Through its social programmes, Adamed supports the development of science in Poland, educates the public, and contributes to health promotion and disease prevention. The aim of our activities is to reach as many recipients as possible and to significantly influence positive social changes.



Adamed for the Family

In 2022, the **Adamed for the Family** campaign took place, as part of which more than 2,000 free medical examinations and consultations were carried out in 6 Polish cities. An additional activity as part of the initiative was to check the health of Poles, and the results were presented in an extensive report with experts' comments.



Adamed for Seniors (Adamed dla Seniora)


The **Adamed for Seniors** programme is our answer to the challenges faced by seniors in the 21st century and aims to engage that age group to lead a more active lifestyle. Adamed supports seniors, helping to educate and encourage them to be more active and to work on their well-being and physical fitness. We also carry out activities promoting health prevention to detect health problems earlier and to challenge the stereotypes associated with senior citizens' everyday lives. We want older people to enjoy a healthy life for as long as possible, as well as to pursue and develop their interests.

Adamed for Seniors covers two key areas of activity:

- Strategic partnerships with the Nationwide Association of Universities of the Third Age, the Manko Association, and the National Institute for Seniors, through which we have helped educate senior citizens across Poland.
- Partnerships at events for senior citizens.



www.adameddlaseniora.pl



Find Yourself (Odnaleźć siebie)

The **Find Yourself** programme is intended to raise awareness and to expand the knowledge about nervous system disorders and diseases among the general public, as well as to overcome social barriers related to the treatment of psychological and neurological symptoms. The concept behind the programme is to foster awareness of the importance of diagnostics and early treatment of mental and neurological disorders. It is also intended to disseminate knowledge about disorders such as schizophrenia, bipolar disorder, depression, epilepsy, Alzheimer's disease, and Parkinson's disease.



www.odnalezcziebie.pl



New at Heart (Serce na nowo)

As part of its education and information programme, Adamed has worked to improve the social and professional lives of those with cardiovascular diseases since 2008. The programme is designed to challenge stereotypes and convince the public that those with cardiovascular disease can lead an active lifestyle and have satisfying careers. It offers additional insights on preventing cardiovascular disease and living a socially and professionally active life, despite certain health problems.



serce **na nowo**

www.sercenanowo.pl

Deep Breath (Głęboki Oddech)

Deep Breath is Adamed's nationwide preventative healthcare and awareness-raising programme designed to increase public awareness of the causes and consequences of respiratory diseases, such as asthma, chronic obstructive pulmonary disease (COPD), croup syndrome, and allergies.



www.glebokiodech.pl

S Help for Ukraine

Adamed Pharma

- Donation of support, including drugs and medical aid with a total value of almost EUR 4 million by 30.06.2024.
- Donation to the Polish Medical Mission.
- Material and psychological assistance for Ukrainian Associates and their families.
- Grassroots volunteering campaigns of Associates.

Adamed Foundation

- 2,100 school kits for Ukrainian children who started their education in Polish schools.
- Development of Ukrainian language versions of educational and educational films as part of the ADAMED SmartUP programme.
- Donation to the SOS Children's Villages Association in Poland.



Delivery of school kits for 2,100 Ukrainian children.



Adamed Foundation



The **Adamed Foundation** was established to support research and development and scientific and educational activities in the field of exact and natural sciences. The Foundation promotes cooperation in the scientific community, as well as the pharmaceutical, medical, and biotechnology industries. It strengthens cooperation with entities with similar roles and objectives operating in Poland and abroad. One of the Foundation's key tasks is to support young talented people.



ADAMED SmartUP

ADAMED SmartUP is an innovative education programme for secondary school students. The aim of the programme is to promote natural and life sciences among young people in Poland and to support the educational development of the most talented students. The basis of the initiative is the www.adamedsmartup.pl on-line platform and a scholarship program for adolescents aged 14–18 years. The programme was conducted under the honorary auspices of the Ministry of Education and Science, the National Centre for Research and Development, the Warsaw University of Technology, the Polish Academy of Sciences, the Warsaw University of Life Sciences, and many other renowned universities in Poland.

www.adamedsmartup.pl



Adamed Expert Foundation

The Adamed Foundation has long been involved in supporting science and working with the scientific community, recognizing science as the most important vehicle for changing the world for the better. In 2020, the Foundation launched the Adamed Expert Foundation programme, which is aimed to create and disseminate reliable, expert information on medicine and health prevention. The programme is directed by the Adamed Expert Foundation Scientific Council made up of eminent members of the Polish scientific community.



ADAMED SmartUP in Poland:

Educational Platform:



Over **200** educational videos



@adamed_smartup



/ADAMEDSmartUP



@ADAMEDSmartUP

10 years of Scholarship Programme:



about **80.000**
registered participants

500
participants of an innovative
science camp



100
main prize winners

27
scholarships awarded



ADAMED SmartUP Academy:



over **2,000**
participants of free science workshops



over **700** hours of classes

Roadshow - showcase lessons in Polish schools:

almost **80** Polish cities

over **150** schools

nearly **16,300** students



ADAMED SmartUP abroad:

Spain:



2 editions, almost 200 participants



Vietnam:



5 editions, almost 750 participants



Uzbekistan:



1 edition, almost 20 participants



S Supportive School

Supportive School is the first comprehensive programme in Poland, inaugurated in the autumn 2023, concerning the prevention of suicidal behaviour among children and young people, carried out in cooperation between the Adamed Foundation and leading suicidology experts working for the Let's Talk About Life service. The initiative has received honorary patronage from the Minister of National Education Republic of Poland as well as substantive support from the Polish Psychiatric Association and the Polish Association of Suicidology. Its partner is Adamed Pharma.

The programme is aimed at primary and secondary schools. It includes people in mental crisis, their peers, parents and employees of educational institutions: headmasters, teachers, pedagogues or school psychologists. In addition, the freely available educational content on the website wspierajacaszkola.pl can be accessed by anyone interested in this topic.

The aim of the Supportive School Programme is to build awareness of mental wellbeing among children, young people, teachers and parents, to give adults and young people tools to prevent risky behaviour, and to teach adults how to be supportive of young people in mental crisis, how to provide and where to seek help.

As part of the Programme, we equip adults with the knowledge necessary to help young people in mental crisis by organising training and consultations on the subject, professional support in creating a crisis procedure and setting up a crisis team at school, and access to educational materials developed specifically for the Programme. A facility that benefits from the whole package of services receives a 'Supportive School' certificate, which is a signal that the topic of students' mental health is as high a priority in the establishment as the quality of teaching.

By mid-2024, as part of the pilot and first edition of the Programme, a total of 30 educational facilities in all provinces in Poland had been covered by educational activities.



**Supportive
School**
ADAMED FOUNDATION

www.wspierajacaszkola.pl



G

Responsible Business Conduct



Membership in the Polish Employers' Union of the Pharmaceutical Industry makes us a signatory of the Medicines for Europe Code of Ethics. This organization brings together the leading European manufacturers of generic and biosimilar medicines. The ethical standards and norms outlined in the Medicines for Europe Code of Ethics are implemented in our policies and procedures. A testament to this commitment is our annual Transparency Report, published since 2018, which details our cooperation with the medical community.



The „1 company – 1 standard” approach: EU-GMP standard implemented in Poland and Vietnam. Good Manufacturing Practice (GMP) is a set of standards applied to ensure the high quality of materials used in the production of a given product.



Active membership in various industry organizations, including: Polish Association of Pharmaceutical Industry Employers (PZPPF), Polish Association of Self Medication Industry (PASMI), Chamber of Commerce „PHARMACY POLSKA”, European Standards Medicines (ESM), the Health Committee of the Polish-Ukrainian Chamber of Commerce, and the „Polish Recycling” Association.

43% of top executives are women

0

violations recorded in terms of corruption, protection of privacy, protection of market practices



Adamed Pharma S.A.

Pieńków, 6a Mariana Adamkiewicza Street,
05-152 Czosnów, Poland
tel.: +48 22 732 77 00
e-mail: adamed@adamed.com
www.adamed.com

